Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer

Despite the recent approval and widespread use of abiraterone acetate and enzalutamide for the treatment of castration-resistant prostate cancer (CRPC), this disease still poses significant management challenges because of various tumor escape mechanisms, including those that allow androgen receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Antonarakis, Emmanuel S., Chandhasin, Chandtip, Osbourne, Erica, Luo, Jun, Sadar, Marianne D., Perabo, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153341/
https://www.ncbi.nlm.nih.gov/pubmed/27628492
http://dx.doi.org/10.1634/theoncologist.2016-0161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153341/
https://www.ncbi.nlm.nih.gov/pubmed/27628492
http://dx.doi.org/10.1634/theoncologist.2016-0161

Ejemplares similares